Vacancy for a dentist in Africa . Contact : kadam.karishma@gmail.com

  • Sharebar

Arestin(TM) In the Adjunctive Treatment of Periodontal Disea

1 reply [Last post]
tirath's picture
Offline
Joined: 31 Oct 2009

Arestin(TM), a locally delivered antibiotic (Minocycline Microspheres), is administered to patients with periodontitis as adjunct to SRP procedures. Arestin(TM) is the lead product of OraPharma, Inc. , a specialty pharmaceutical company with an initial focus on the emerging field of oral health care.

up
0 users have Like. User Likes
sushantpatel_doc's picture
Offline
Joined: 30 Nov 2009
Effects of Doxycycline slow release adjunctive to mechanical

Effects of Doxycycline slow release adjunctive to mechanical nonsurgical therapy.

Objectives: -to evaluate the therapeutic effects of biodegradable doxycycline slow release (14%) gel (DSRG) adjunctively administered to non-surgical therapy in a multi-center, randomized controlled, parallel group trial after three months. (Interim analysis) Material & Methods: In 5 clinical centers, randomization assigned 61 test and 58 control patients with moderate to severe recurrent periodontitis to mechanical ultrasonic/sonic instrumentation with (T) and without (C) subsequent administration of a 14% DSRG into residual periodontal pockets of at least 5mm depth and bleeding on probing (BOP). Therapeutic effects were evaluated on a short term basis (3 months) as changes of pocket probing depth (PPD), in BOP, treatment time, probing attachment levels and need for re-treatment. Safety and tolerability parameters were evaluated as well. An interim analysis of the data was performed after 3 months with a planned continuation of the study for 6 and 12 months after intervention. Results: At baseline, the two groups were comparable with regards to demographic data and mean PPD. The DSRG treated patients showed a significantly higher decrease in PPD than the control group (.0.79mm vs. 0.65mm, p=0.0013). In absolute values, PPD decreased from 4.67mm to 3.89mm in the test and from 4.74mm to 4.1mm in the control group, respectively. A multilevel analysis showed that 90% of the variance were due to the treatment effect, while 5% of the variance were due to center and patient effects. 9 minor adverse effects, not related to the trial medication were reported. Conclusion: Beneficial clinical effects (reduction in PPD) were documented for DSRG application adjunctive to mechanical debridement for residual pockets in periodontal maintenance patients. DSRG can be considered safe and well tolerated.

up
0 users have Like. User Likes